OMass Therapeutics is a biotechnology company using mass spectrometry platforms for drug discovery and the development of therapeutics that is headquartered in Oxford, United Kingdom and was founded in 2016 by Idlir Liko, Dame Carol Robinson, and Jonathan Hopper.
On June 14, 2016 OMass Therapeutics announced raising £1 million in seed funding from Oxford Sciences Innovation. The company plans on using their seed funding to launch their drug discovery platform and to help establish partnerships with international biotechnology and pharmaceutical companies working in the drug discovery industry. The CEO of OMass Therapeutics, Jonathan Hopper, made the following statement regarding the value his company can bring to other drug discovery companies through partnerships:
OMass will offer pharmaceutical and biotech companies the opportunity to access world-leading structural mass spectrometry technology, without having to set up sophisticated instrumentation and acquire expertise in-house. This provides new ways to study complex protein assemblies and their interactions with other biological molecules.
On November 21, 2018 OMass Therapeutics announced raising £14 million in series A funding from Syncona Partners LLP (lead investor), and Oxford Sciences Innovation. The company plans on using their series A funding to develop its structural mass spectrometry technology. The founder and scientific advisor of OMass Therapeutics made the following statement regarding the company's series A funding:
It is very exciting for me to see the company take this new direction following Syncona investment. Having devoted my career to developing these mass spectrometry approaches I am now looking forward to demonstrating just how powerful they can be.
On February 17, 2020 OMass Technologies announced raising £27.5 million in follow-on series A funding from Syncona Partners LLP, Oxford Sciences Innovation, and Oxford University. The company plans on using their follow-on series A funding to fund a pipeline of therapeutic drugs to treat patients with immunological and genetic disorders.